爱科百发宣布爱司韦™在治疗呼吸道合胞病毒（RSV）感染的住院婴幼儿中的临床三期试验达到主要终点
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在临床三期AirFLO试验中，爱司韦™与安慰剂相比显著降低症状评分（p=0.002）及病毒载量（p=0.006），达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
愛科百發宣佈愛司韋™在治療呼吸道合胞病毒（RSV）感染的住院嬰幼兒中的臨床三期試驗達到主要終點
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在臨床三期AirFLO試驗中，愛司韋™與安慰劑相比顯著降低症狀評分（p=0.002）及病毒載量（p=0.006），達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...
ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...
FDA Granted Pediatric Disease Designation for OXi-4503
September 16, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics...
Peripheral Intravenous Catheters Market To Reach USD 7.52 Billion By 2027 | Reports and Data
March 04, 2020 12:00 ET
|
Reports and Data
New York, March 04, 2020 (GLOBE NEWSWIRE) -- The global Peripheral Intravenous Catheters market is forecast to reach USD 7.52 Billion by 2027, according to a new report by Reports and Data....
EB Research Partnership and EB Research Foundation Join Forces to Advance Breakthroughs in Epidermolysis Bullosa Research
August 27, 2018 19:00 ET
|
EB Research Partnership
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), based in New York, and Australian-based EB Research Foundation, today announced a global collaboration to accelerate their...